Friday, September 2, 2016

BRIEF-Merck provides update on odanacatib development program

* To discontinue development after independent adjudication

of major adverse cardiovascular events confirmed an increased

risk of stroke

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)